Russian Cancer Drugs For Home Market?

20 January 1997

Russian specialists are reported to have developed a number of newanticancer preparations to be launched by the domestic drug industry, according to sources at a joint session in Moscow devoted to the interim results of two state programs, one for the promotion of domestic anticancer drugs. However, no details were available as to the nature of the drugs.

It was also reported to the session that testing of what were described as "complex mineral preparations" for tumor therapy had been successful.

The other state program discussed by boards of the Health Ministry and the State Committee for new Technologies related to the development of cancer management techniques. The two cancer control programs were started in early 1995 in response to data showing that malignancies continued to be a major cause of death in Russia, second only to cardiovascular disorders. However, media reports suggest that not much progress was made because of cash shortages until the Moscow city government started to invest in both projects.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight